Novel therapeutic targets for sepsis: Regulation of exaggerated inflammatory responses

Journal of Nippon Medical School

Volumn 79, Issue 1, 2012, Pages 4-18

  Matsuda, Akihisa ^a,b   Jacob, Asha ^a   Wu, Rongqian ^a   Aziz, Monowar ^a   Yang, Weng Lang ^a   Matsutani, Takeshi ^b   Suzuki, Hideyuki ^b   Furukawa, Kiyonori ^b   Uchida, Eiji ^b   Wang, PingWang ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cholinergic pathway; Inflammasome; Inflammation; MFG E8; Sepsis; Stem cells

Indexed keywords

[4 [(3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYL]TRIMETHYLAMMONIUM; CRYOPYRIN; GHRELIN; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LACTADHERIN; LEUCINE RICH REPEAT KINASE 2; METHOCTRAMINE; MUSCARINE; OPSONIN; SEMAPIMOD; TOLL LIKE RECEPTOR;

APOPTOSIS; CENTRAL NERVOUS SYSTEM; CHOLINERGIC ACTIVITY; DOWN REGULATION; EMBRYONIC STEM CELL; HUMAN; IMMUNOCOMPETENT CELL; MESENCHYMAL STEM CELL; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PROTEIN EXPRESSION; REVIEW; SEPSIS; STEM CELL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VAGUS NERVE;

ANIMALS; CASPASE 1; HUMANS; INFLAMMASOMES; INFLAMMATION; MOLECULAR TARGETED THERAPY; SEPSIS; STEM CELLS;

EID: 84863165443     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.79.4     Document Type: Review

References (124)

1. Kung HC, Hoyert DL, Xu J, Murphy SL: Deaths: final data for 2005. Natl Vital Stat Rep 2008; 56: 1120.
2. Melamed A, Sorvillo FJ: The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Crit Care 2009; 13: R28.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
4. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007; 35: 1244-1250.
5. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 15461554.
6. Russell JA: Management of sepsis. N Engl J Med 2006; 355: 1699-1713.
7. Oberholzer C, Oberholzer A, Clare-Salzler M, Moldawer LL: Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J 2001; 15: 879-892.
8. Riedemann NC, Guo RF, Ward PA: Novel strategies for the treatment of sepsis. Nat Med 2003; 9: 517524.
9. van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367.
10. Bone RC, Balk RA, Cerra FB, et al.: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
11. Abraham E, Matthay MA, Dinarello CA, et al.: Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit Care Med 2000; 28: 232-235.
12. Matot I, Sprung CL: Definition of sepsis. Intensive Care Med 2001; 27 Suppl 1: S3-9.
13. Dellinger RP, Levy MM, Carlet JM, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
14. Houston G, Cuthbertson BH: Activated protein C for the treatment of severe sepsis. Clin Microbiol Infect 2009; 15: 319-324.
15. Cai B, Deitch EA, Ulloa L: Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm 2010; 2010: 642462.
16. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138150.
17. Riedemann NC, Ward PA: Anti-inflammatory strategies for the treatment of sepsis. Expert Opin Biol Ther 2003; 3: 339-350.
18. Mira JP, Cariou A, Grall F, et al.: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282: 561-568.
19. van der Poll T, Lowry SF: Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock 1995; 3: 1-12.
20. Moshage H: Cytokines and the hepatic acute phase response. J Pathol 1997; 181: 257-266.
21. Beasley D, Schwartz JH, Brenner BM: Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 1991; 87: 602-608.
22. Chapman PB, Lester TJ, Casper ES, et al.: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1987; 5: 1942-1951.
23. Dinarello CA: Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997; 112: 321S-329S.
24. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162-1172.
25. van der Poll T, Buller HR, ten Cate H, et al.: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627.
26. Kast RE: Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMP. Int J Immunopharmacol 2000; 22: 1001-1006.
27. Kawai T, Akira S: TLR signaling. Semin Immunol 2007; 19: 24-32.
28. Creagh EM, O'Neill LA: TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006; 27: 352-357.
29. Uematsu S, Akira S: Toll-like receptors and innate immunity. J Mol Med 2006; 84: 712-725.
30. van der Poll T, Opal SM: Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8: 3243.
31. Wagner H: Endogenous TLR ligands and autoimmunity. Adv Immunol 2006; 91: 159-173.
32. Cinel I, Opal SM: Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009; 37: 291304.
33. Kawai T, Akira S: The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009; 21: 317-337.
34. Kumar H, Kawai T, Akira S: Pathogen recognition by the innate immune system. Int Rev Immunol 2011; 30: 16-34.
35. Barnich N, Aguirre JE, Reinecker HC, Xavier R, Podolsky DK: Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-kappa[B activation in muramyl dipeptide recognition. J Cell Biol 2005; 170: 21-26.
36. Kufer TA, Kremmer E, Adam AC, Philpott DJ, Sansonetti PJ: The pattern-recognition molecule Nod1 is localized at the plasma membrane at sites of bacterial interaction. Cell Microbiol 2008; 10: 477486.
37. Mariathasan S, Monack DM: Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007; 7: 31-40.
38. Pedra JH, Cassel SL, Sutterwala FS: Sensing pathogens and danger signals by the inflammasome. Curr Opin Immunol 2009; 21: 10-16.
39. Ogura Y, Sutterwala FS, Flavell RA: The inflammasome: first line of the immune response to cell stress. Cell 2006; 126: 659-662.
40. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G: The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009; 10: 241-247.
41. Franchi L, Warner N, Viani K, Nunez G: Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 2009; 227: 106-128.
42. Zhang L, Lu R, Zhao G, Pflugfelder SC, Li DQ: TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int J Biochem Cell Biol (in press).
43. Sarkar A, Hall MW, Exline M, et al.: Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis independently of interleukin-1beta and interleukin-18. Am J Respir Crit Care Med 2006; 174: 1003-1010.
44. Lamkanfi M, Sarkar A, Vande Walle L, et al.: Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol 2010; 185: 43854392.
45. Mariathasan S, Newton K, Monack DM, et al.: Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004; 430: 213-218.
46. Sutterwala FS, Ogura Y, Szczepanik M, et al.: Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006; 24: 317-327.
47. Saleh M, Mathison JC, Wolinski MK, et al.: Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 2006; 440: 10641068.
48. Fahy RJ, Exline MC, Gavrilin MA, et al.: Inflammasome mRNA expression in human monocytes during early septic shock. Am J Respir Crit Care Med 2008; 177: 983-988.
49. Nathan C: Points of control in inflammation. Nature 2002; 420: 846-852.
50. Tracey KJ: The inflammatory reflex. Nature 2002; 420: 853-859.
51. Tracey KJ: Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007; 117: 289-296.
52. Bernik TR, Friedman SG, Ochani M, et al.: Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med 2002; 195: 781-788.
53. Borovikova LV, Ivanova S, Zhang M, et al.: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-462.
54. Huston JM, Ochani M, Rosas-Ballina M, et al.: Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 2006; 203: 1623-1628.
55. Pavlov VA, Ochani M, Gallowitsch-Puerta M, et al.: Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc Natl Acad Sci U S A 2006; 103: 5219-5223.
56. Wang H, Yu M, Ochani M, et al.: Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384388.
57. Wang H, Liao H, Ochani M, et al.: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10: 1216-1221.
58. de Jonge WJ, van der Zanden EP, The FO, et al.: Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 2005; 6: 844-851.
59. Smoak KA, Cidlowski JA: Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 2004; 125: 697-706.
60. Song XM, Li JG, Wang YL, et al.: The protective effect of the cholinergic anti-inflammatory pathway against septic shock in rats. Shock 2008; 30: 468472.
61. van Westerloo DJ, Giebelen IA, Meijers JC, et al.: Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats. J Thromb Haemost 2006; 4: 1997-2002.
62. Giebelen IA, van Westerloo DJ, LaRosa GJ, de Vos AF, van der Poll T: Stimulation of alpha 7 cholinergic receptors inhibits lipopolysaccharide-induced neutrophil recruitment by a tumor necrosis factor alpha-independent mechanism. Shock 2007; 27: 443-447.
63. Pavlov VA, Ochani M, Yang LH, et al.: Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med 2007; 35: 1139-1144.
64. Cheyuo C, Wu R, Zhou M, Jacob A, Coppa G, Wang P: Ghrelin suppresses inflammation and neuronal nitric oxide synthase in focal cerebral ischemia via the vagus nerve. Shock 2011; 35: 258-265.
65. Jacob A, Shah KG, Wu R, Wang P: Ghrelin as a novel therapy for radiation combined injury. Mol Med 2010; 16: 137-143.
66. Shah KG, Wu R, Jacob A, et al.: Human ghrelin ameliorates organ injury and improves survival after radiation injury combined with severe sepsis. Mol Med 2009; 15: 407-414.
67. Wu JT, Kral JG: Ghrelin: integrative neuroendocrine peptide in health and disease. Ann Surg 2004; 239: 464-474.
68. Wu R, Dong W, Cui X, et al.: Ghrelin down- regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg 2007; 245: 480-486.
69. Wu R, Dong W, Ji Y, et al.: Orexigenic hormone ghrelin attenuates local and remote organ injury after intestinal ischemia-reperfusion. PLoS One 2008; 3: e2026.
70. Wu R, Dong W, Qiang X, et al.: Orexigenic hormone ghrelin ameliorates gut barrier dysfunction in sepsis in rats. Crit Care Med 2009; 37: 2421-2426.
71. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
72. Dixit VD, Schaffer EM, Pyle RS, et al.: Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 5766.
73. Taub DD: Novel connections between the neuroendocrine and immune systems: the ghrelin immunoregulatory network. Vitam Horm 2008; 77: 325-346.
74. Banks WA, Tschop M, Robinson SM, Heiman ML: Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 2002; 302: 822-827.
75. Cowley MA, Smith RG, Diano S, et al.: The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003; 37: 649-661.
76. Wu R, Zhou M, Cui X, Simms HH, Wang P: Ghrelin clearance is reduced at the late stage of polymicrobial sepsis. Int J Mol Med 2003; 12: 777781.
77. McCulloch EA, Till JE: Perspectives on the properties of stem cells. Nat Med 2005; 11: 1026-16
78. Ferrari G, Cusella-De A.G, Coletta M, et al.: Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279: 1528-1530.
79. Alison MR, Poulsom R, Jeffery R, et al.: Hepatocytes from non-hepatic adult stem cells. Nature 2000; 406: 257.
80. Hayashi Y, Tsuji S, Tsujii M, et al.: The transdifferentiation of bone-marrow-derived cells in colonic mucosal regeneration after dextran-sulfate-sodium-induced colitis in mice. Pharmacology 2007; 80: 193-199.
81. Kopen GC, Prockop DJ, Phinney DG: Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A 1999; 96: 10711-10716.
82. Korbling M, Katz RL, Khanna A, et al.: Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 2002; 346: 738-746.
83. Poulsom R, Forbes SJ, Hodivala-Dilke K, et al.: Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol 2001; 195: 229-235.
84. Gnecchi M, He H, Noiseux N, et al.: Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006; 20: 661-669.
85. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C: Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289: F31-42.
86. Wang M, Tsai BM, Crisostomo PR, Meldrum DR: Pretreatment with adult progenitor cells improves recovery and decreases native myocardial proinflammatory signaling after ischemia. Shock 2006; 25: 454-459.
87. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA: Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007; 179: 1855-1863.
88. Krasnodembskaya A, Song Y, Fang X, et al.: Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010; 28: 2229-2238.
89. Mei SH, Haitsma JJ, Dos Santos CC, et al.: Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010; 182: 1047-1057.
90. Nauta AJ, Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-3506.
91. Rojas M, Xu J, Woods CR, et al.: Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005; 33: 145-152.
92. Dominici M, Le Blanc K, Mueller I, et al.: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
93. Crisostomo PR, Markel TA, Wang Y, Meldrum DR: Surgically relevant aspects of stem cell paracrine effects. Surgery 2008; 143: 577-581.
94. Nemeth K, Leelahavanichkul A, Yuen PS, et al.: Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-49.
95. Xu J, Woods CR, Mora AL, et al.: Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 2007; 293: L131-141.
96. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA: Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A 2009; 106: 16357-16362.
97. Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Buscher D, Delgado M: Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009; 58: 929939.
98. Fink SL, Cookson BT: Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 2005; 73: 1907-1916.
99. Bell CW, Jiang W, Reich CF 3rd, Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291: C1318-1325.
100. Silva MT, do Vale A, dos Santos NM: Secondary necrosis in multicellular animals: an outcome of apoptosis with pathogenic implications. Apoptosis 2008; 13: 463-482.
101. Zheng L,He M,Long M,Blomgran R,Stendahl O: Pathogen-induced apoptotic neutrophils express heat shock proteins and elicit activation of human macrophages. J Immunol 2004; 173: 6319-6326.
102. Hotchkiss RS, Chang KC, Grayson MH, et al.: Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc Natl Acad Sci U S A 2003; 100: 6724-6729.
103. Chung CS, Xu YX, Chaudry IH, Ayala A: Sepsis induces increased apoptosis in lamina propria mononuclear cells which is associated with altered cytokine gene expression. J Surg Res 1998; 77: 6370.
104. Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006; 6: 813-822.
105. Wang SD, Huang KJ, Lin YS, Lei HY: Sepsisinduced apoptosis of the thymocytes in mice. J Immunol 1994; 152: 5014-5021.
106. Stubbs JD, Lekutis C, Singer KL, et al.: cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences. Proc Natl Acad Sci U S A 1990; 87: 8417-8421.
107. Aziz MM, Ishihara S, Mishima Y, et al.: MFG-E8 attenuates intestinal inflammation in murine experimental colitis by modulating osteopontin-dependent alphavbeta3 integrin signaling. J Immunol 2009; 182: 7222-7232.
108. Hanayama R, Tanaka M, Miyasaka K, et al.: Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 2004; 304: 1147-1150.
109. Aoki N, Kishi M, Taniguchi Y, Adachi T, Nakamura R, Matsuda T: Molecular cloning of glycoprotein antigens MGP57/53 recognized by monoclonal antibodies raised against bovine milk fat globule membrane. Biochim Biophys Acta 1995; 1245: 385391.
110. Andersen MH, Graversen H, Fedosov SN, Petersen TE, Rasmussen JT: Functional analyses of two cellular binding domains of bovine lactadherin. Biochemistry 2000; 39: 6200-6206.
111. Raymond A, Ensslin MA, Shur BD: SED1 /MFG-E8: a bi-motif protein that orchestrates diverse cellular interactions. J Cell Biochem 2009; 106: 957-966.
112. Henson PM: Dampening inflammation. Nat Immunol 2005; 6: 1179-1181.
113. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF- beta, PGE2, and PAF. J Clin Invest 1998; 101: 890898.
114. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I: Immunosuppressive effects of apoptotic cells. Nature 1997; 390: 350-351.
115. Miksa M, Amin D, Wu R, et al.: Maturation-induced down-regulation of MFG-E8 impairs apoptotic cell clearance and enhances endotoxin response. Int J Mol Med 2008; 22: 743-748.
116. Bu HF, Zuo XL, Wang X, et al.: Milk fat globule- EGF factor 8/lactadherin plays a crucial role in maintenance and repair of murine intestinal epithelium. J Clin Invest 2007; 117: 3673-3683.
117. Matsuda A, Jacob A, Wu R, et al.: Milk fat globule- EGF factor VIII in sepsis and ischemia-reperfusion injury. Mol Med 2011; 17: 126-133.
118. Miksa M, Komura H, Wu R, Shah KG, Wang P: A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester. J Immunol Methods 2009; 342: 71-77.
119. Miksa M,Wu R,Dong W,Das P,Yang D,Wang P: Dendritic cell-derived exosomes containing milk fat globule epidermal growth factor-factor VIII attenuate proinflammatory responses in sepsis. Shock 2006; 25: 586-593.
120. Cui T, Miksa M, Wu R, et al.: Milk fat globule epidermal growth factor 8 attenuates acute lung injury in mice after intestinal ischemia and reperfusion. Am J Respir Crit Care Med 2010; 181: 238-246.
121. Matsuda A, Wu R, Jacob A, et al.: Protective effect of milk fat globule-epidermal growth factor-factor VIII after renal ischemia-reperfusion injury in mice. Crit Care Med (in press).
122. Komura H, Miksa M, Wu R, Goyert SM, Wang P: Milk fat globule epidermal growth factor-factor VIII is down-regulated in sepsis via the lipopolysaccharide-CD14 pathway. J Immunol 2009; 182: 581-587.
123. Miksa M, Wu R, Dong W, et al.: Immature dendritic cell-derived exosomes rescue septic animals via milk fat globule epidermal growth factor-factor VIII [corrected]. J Immunol 2009; 183: 5983-5990.
124. Aziz M, Jacob A, Matsuda A, Wang P: Milk fat globulin-EGF factor 8 expression, function and plausible signal transduction in resolving inflammation. Apoptosis (in pres).